kn 62 Search Results


camkii inhibitor  (Tocris)
95
Tocris camkii inhibitor
Effect of PYP pretreatment on PFOS-induced GRP78 expression and its underlying mechanisms. Inhibition of <t>CaMKII</t> <t>and</t> <t>JNK</t> phosphorylation with <t>KN62</t> (10 µM) and SP600125 (10 µM), respectively, decreased the PFOS-induced increase in GRP78 expression as effectively as the PYP (1 µg/mL) pretreatment. The PYP-induced decrease in GRP78 expression was abolished by blocking the TrkB receptor and inhibiting PI3K and ERK1/2 activation with cyclotraxin B (200 nM), LY294002 (20 µM), and SL327 (10 µM), respectively. The data were expressed as the mean ± SEM of three independent experiments, each performed in triplicate. * p < 0.05 versus control group; # p < 0.05 versus PFOS treatment; ## p < 0.05 versus PYP pretreatment; Cont, control.
Camkii Inhibitor, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/camkii inhibitor/product/Tocris
Average 95 stars, based on 1 article reviews
camkii inhibitor - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier
n o bis 5 isoquinolinesufonyll n methyl l tyrosyl 4 phenyl piperazine kn62 tocris bioscience  (Tocris)
93
Tocris n o bis 5 isoquinolinesufonyll n methyl l tyrosyl 4 phenyl piperazine kn62 tocris bioscience
The purinergic antagonists Suramin, PPADS, and <t>KN62</t> did not have any significant effect on the production of CCL18 (A; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.) or Il-1ß (B; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.). The pre-incubation of monocytes with inhibitors before ATP stimulation did not have any significant effect on the ATP-induced reduction in CCL18 levels (C; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, p = n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, p = n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, p = n.s.;) or on IL-1β levels (D; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, n.s)
N O Bis 5 Isoquinolinesufonyll N Methyl L Tyrosyl 4 Phenyl Piperazine Kn62 Tocris Bioscience, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/n o bis 5 isoquinolinesufonyll n methyl l tyrosyl 4 phenyl piperazine kn62 tocris bioscience/product/Tocris
Average 93 stars, based on 1 article reviews
n o bis 5 isoquinolinesufonyll n methyl l tyrosyl 4 phenyl piperazine kn62 tocris bioscience - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
kn 62  (Selleck Chemicals)
93
Selleck Chemicals kn 62
The purinergic antagonists Suramin, PPADS, and <t>KN62</t> did not have any significant effect on the production of CCL18 (A; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.) or Il-1ß (B; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.). The pre-incubation of monocytes with inhibitors before ATP stimulation did not have any significant effect on the ATP-induced reduction in CCL18 levels (C; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, p = n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, p = n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, p = n.s.;) or on IL-1β levels (D; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, n.s)
Kn 62, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/kn 62/product/Selleck Chemicals
Average 93 stars, based on 1 article reviews
kn 62 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
s6787 kn62  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology s6787 kn62
The purinergic antagonists Suramin, PPADS, and <t>KN62</t> did not have any significant effect on the production of CCL18 (A; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.) or Il-1ß (B; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.). The pre-incubation of monocytes with inhibitors before ATP stimulation did not have any significant effect on the ATP-induced reduction in CCL18 levels (C; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, p = n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, p = n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, p = n.s.;) or on IL-1β levels (D; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, n.s)
S6787 Kn62, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/s6787 kn62/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
s6787 kn62 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
inhibitors h7 or h8  (Seikagaku corporation)
90
Seikagaku corporation inhibitors h7 or h8
The purinergic antagonists Suramin, PPADS, and <t>KN62</t> did not have any significant effect on the production of CCL18 (A; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.) or Il-1ß (B; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.). The pre-incubation of monocytes with inhibitors before ATP stimulation did not have any significant effect on the ATP-induced reduction in CCL18 levels (C; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, p = n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, p = n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, p = n.s.;) or on IL-1β levels (D; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, n.s)
Inhibitors H7 Or H8, supplied by Seikagaku corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/inhibitors h7 or h8/product/Seikagaku corporation
Average 90 stars, based on 1 article reviews
inhibitors h7 or h8 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
cam kinase inhibitor kn62  (Biomol GmbH)
90
Biomol GmbH cam kinase inhibitor kn62
The purinergic antagonists Suramin, PPADS, and <t>KN62</t> did not have any significant effect on the production of CCL18 (A; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.) or Il-1ß (B; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.). The pre-incubation of monocytes with inhibitors before ATP stimulation did not have any significant effect on the ATP-induced reduction in CCL18 levels (C; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, p = n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, p = n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, p = n.s.;) or on IL-1β levels (D; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, n.s)
Cam Kinase Inhibitor Kn62, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cam kinase inhibitor kn62/product/Biomol GmbH
Average 90 stars, based on 1 article reviews
cam kinase inhibitor kn62 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
camkii reagents kn-62  (LC Laboratories)
90
LC Laboratories camkii reagents kn-62
The purinergic antagonists Suramin, PPADS, and <t>KN62</t> did not have any significant effect on the production of CCL18 (A; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.) or Il-1ß (B; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.). The pre-incubation of monocytes with inhibitors before ATP stimulation did not have any significant effect on the ATP-induced reduction in CCL18 levels (C; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, p = n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, p = n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, p = n.s.;) or on IL-1β levels (D; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, n.s)
Camkii Reagents Kn 62, supplied by LC Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/camkii reagents kn-62/product/LC Laboratories
Average 90 stars, based on 1 article reviews
camkii reagents kn-62 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
kn-62 (camkii-specific inhibitor)  (Enzo Biochem)
90
Enzo Biochem kn-62 (camkii-specific inhibitor)
The purinergic antagonists Suramin, PPADS, and <t>KN62</t> did not have any significant effect on the production of CCL18 (A; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.) or Il-1ß (B; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.). The pre-incubation of monocytes with inhibitors before ATP stimulation did not have any significant effect on the ATP-induced reduction in CCL18 levels (C; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, p = n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, p = n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, p = n.s.;) or on IL-1β levels (D; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, n.s)
Kn 62 (Camkii Specific Inhibitor), supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/kn-62 (camkii-specific inhibitor)/product/Enzo Biochem
Average 90 stars, based on 1 article reviews
kn-62 (camkii-specific inhibitor) - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
kn-62  (Cayman Chemical)
90
Cayman Chemical kn-62
The purinergic antagonists Suramin, PPADS, and <t>KN62</t> did not have any significant effect on the production of CCL18 (A; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.) or Il-1ß (B; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.). The pre-incubation of monocytes with inhibitors before ATP stimulation did not have any significant effect on the ATP-induced reduction in CCL18 levels (C; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, p = n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, p = n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, p = n.s.;) or on IL-1β levels (D; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, n.s)
Kn 62, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/kn-62/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
kn-62 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
kn-62  (Biaffin Inc)
90
Biaffin Inc kn-62
The purinergic antagonists Suramin, PPADS, and <t>KN62</t> did not have any significant effect on the production of CCL18 (A; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.) or Il-1ß (B; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.). The pre-incubation of monocytes with inhibitors before ATP stimulation did not have any significant effect on the ATP-induced reduction in CCL18 levels (C; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, p = n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, p = n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, p = n.s.;) or on IL-1β levels (D; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, n.s)
Kn 62, supplied by Biaffin Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/kn-62/product/Biaffin Inc
Average 90 stars, based on 1 article reviews
kn-62 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
kn-62  (Microm International GmbH)
90
Microm International GmbH kn-62
The purinergic antagonists Suramin, PPADS, and <t>KN62</t> did not have any significant effect on the production of CCL18 (A; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.) or Il-1ß (B; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.). The pre-incubation of monocytes with inhibitors before ATP stimulation did not have any significant effect on the ATP-induced reduction in CCL18 levels (C; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, p = n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, p = n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, p = n.s.;) or on IL-1β levels (D; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, n.s)
Kn 62, supplied by Microm International GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/kn-62/product/Microm International GmbH
Average 90 stars, based on 1 article reviews
kn-62 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
kn-62  (The Company of Biologists)
90
The Company of Biologists kn-62
The purinergic antagonists Suramin, PPADS, and <t>KN62</t> did not have any significant effect on the production of CCL18 (A; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.) or Il-1ß (B; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.). The pre-incubation of monocytes with inhibitors before ATP stimulation did not have any significant effect on the ATP-induced reduction in CCL18 levels (C; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, p = n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, p = n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, p = n.s.;) or on IL-1β levels (D; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, n.s)
Kn 62, supplied by The Company of Biologists, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/kn-62/product/The Company of Biologists
Average 90 stars, based on 1 article reviews
kn-62 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


Effect of PYP pretreatment on PFOS-induced GRP78 expression and its underlying mechanisms. Inhibition of CaMKII and JNK phosphorylation with KN62 (10 µM) and SP600125 (10 µM), respectively, decreased the PFOS-induced increase in GRP78 expression as effectively as the PYP (1 µg/mL) pretreatment. The PYP-induced decrease in GRP78 expression was abolished by blocking the TrkB receptor and inhibiting PI3K and ERK1/2 activation with cyclotraxin B (200 nM), LY294002 (20 µM), and SL327 (10 µM), respectively. The data were expressed as the mean ± SEM of three independent experiments, each performed in triplicate. * p < 0.05 versus control group; # p < 0.05 versus PFOS treatment; ## p < 0.05 versus PYP pretreatment; Cont, control.

Journal: Marine Drugs

Article Title: Phycoerythrin Peptide from Pyropia yezoensis Alleviates Endoplasmic Reticulum Stress Caused by Perfluorooctane Sulfonate-Induced Calcium Dysregulation

doi: 10.3390/md16020044

Figure Lengend Snippet: Effect of PYP pretreatment on PFOS-induced GRP78 expression and its underlying mechanisms. Inhibition of CaMKII and JNK phosphorylation with KN62 (10 µM) and SP600125 (10 µM), respectively, decreased the PFOS-induced increase in GRP78 expression as effectively as the PYP (1 µg/mL) pretreatment. The PYP-induced decrease in GRP78 expression was abolished by blocking the TrkB receptor and inhibiting PI3K and ERK1/2 activation with cyclotraxin B (200 nM), LY294002 (20 µM), and SL327 (10 µM), respectively. The data were expressed as the mean ± SEM of three independent experiments, each performed in triplicate. * p < 0.05 versus control group; # p < 0.05 versus PFOS treatment; ## p < 0.05 versus PYP pretreatment; Cont, control.

Article Snippet: JNK inhibitor (SP600125; 10 μM), CaMKII inhibitor (KN62; 10 μM), TrkB receptor antagonist (cyclotraxin B; 200 nM), PI3K inhibitor (LY294002; 20 μM), and ERK1/2 inhibitor (SL327; 10 μM) were obtained from Tocris Bioscience (Minneapolis, MN, USA) and were incubated for 30 min prior to PYP or PFOS treatments.

Techniques: Expressing, Inhibition, Phospho-proteomics, Blocking Assay, Activation Assay, Control

PYP-induced decrease in phosphorylation of JNK linked to CaMKII by PFOS exposure. CaMKII phosphorylation was upregulated due to PFOS exposure and downregulated by PYP (1 µg/mL) pretreatment. The PYP-induced decrease in CaMKII phosphorylation was abolished by blocking the TrkB receptor and inhibiting PI3K and ERK1/2 activation with cyclotraxin B (200 nM), LY294002 (20 µM), and SL327 (10 µM), respectively. Inhibiting JNK did not affect the PFOS-induced increase in CaMKII phosphorylation ( A ); JNK phosphorylation was also downregulated by PYP-induced TrkB receptor-linked ERK1/2 activation. The PFOS-induced increase in JNK phosphorylation was particularly downregulated by inhibiting CaMKII activation with 10 µM of KN62 ( B ). The data were expressed as the mean ± SEM of three independent experiments, each performed in triplicate. * p < 0.05 versus control group; # p < 0.05 versus PFOS treatment; ## p < 0.05 versus PYP pretreatment; Cont, control.

Journal: Marine Drugs

Article Title: Phycoerythrin Peptide from Pyropia yezoensis Alleviates Endoplasmic Reticulum Stress Caused by Perfluorooctane Sulfonate-Induced Calcium Dysregulation

doi: 10.3390/md16020044

Figure Lengend Snippet: PYP-induced decrease in phosphorylation of JNK linked to CaMKII by PFOS exposure. CaMKII phosphorylation was upregulated due to PFOS exposure and downregulated by PYP (1 µg/mL) pretreatment. The PYP-induced decrease in CaMKII phosphorylation was abolished by blocking the TrkB receptor and inhibiting PI3K and ERK1/2 activation with cyclotraxin B (200 nM), LY294002 (20 µM), and SL327 (10 µM), respectively. Inhibiting JNK did not affect the PFOS-induced increase in CaMKII phosphorylation ( A ); JNK phosphorylation was also downregulated by PYP-induced TrkB receptor-linked ERK1/2 activation. The PFOS-induced increase in JNK phosphorylation was particularly downregulated by inhibiting CaMKII activation with 10 µM of KN62 ( B ). The data were expressed as the mean ± SEM of three independent experiments, each performed in triplicate. * p < 0.05 versus control group; # p < 0.05 versus PFOS treatment; ## p < 0.05 versus PYP pretreatment; Cont, control.

Article Snippet: JNK inhibitor (SP600125; 10 μM), CaMKII inhibitor (KN62; 10 μM), TrkB receptor antagonist (cyclotraxin B; 200 nM), PI3K inhibitor (LY294002; 20 μM), and ERK1/2 inhibitor (SL327; 10 μM) were obtained from Tocris Bioscience (Minneapolis, MN, USA) and were incubated for 30 min prior to PYP or PFOS treatments.

Techniques: Phospho-proteomics, Blocking Assay, Activation Assay, Control

Schematic of a proposed mechanism underlying the neuroprotective effects of PYP against PFOS exposure in frontal cortical neurons. The expression level of GRP78 by PFOS exposure is mediated by phosphorylation of JNK linked to CaMKII. PYP downregulates the JNK-mediated increase in ER stress by PFOS via the activation of TrkB receptor-linked ERK1/2 signaling. Thus, PYP protects frontal cortical neurons from ER stress caused by PFOS-induced calcium dysregulation.

Journal: Marine Drugs

Article Title: Phycoerythrin Peptide from Pyropia yezoensis Alleviates Endoplasmic Reticulum Stress Caused by Perfluorooctane Sulfonate-Induced Calcium Dysregulation

doi: 10.3390/md16020044

Figure Lengend Snippet: Schematic of a proposed mechanism underlying the neuroprotective effects of PYP against PFOS exposure in frontal cortical neurons. The expression level of GRP78 by PFOS exposure is mediated by phosphorylation of JNK linked to CaMKII. PYP downregulates the JNK-mediated increase in ER stress by PFOS via the activation of TrkB receptor-linked ERK1/2 signaling. Thus, PYP protects frontal cortical neurons from ER stress caused by PFOS-induced calcium dysregulation.

Article Snippet: JNK inhibitor (SP600125; 10 μM), CaMKII inhibitor (KN62; 10 μM), TrkB receptor antagonist (cyclotraxin B; 200 nM), PI3K inhibitor (LY294002; 20 μM), and ERK1/2 inhibitor (SL327; 10 μM) were obtained from Tocris Bioscience (Minneapolis, MN, USA) and were incubated for 30 min prior to PYP or PFOS treatments.

Techniques: Expressing, Phospho-proteomics, Activation Assay

The purinergic antagonists Suramin, PPADS, and KN62 did not have any significant effect on the production of CCL18 (A; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.) or Il-1ß (B; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.). The pre-incubation of monocytes with inhibitors before ATP stimulation did not have any significant effect on the ATP-induced reduction in CCL18 levels (C; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, p = n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, p = n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, p = n.s.;) or on IL-1β levels (D; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, n.s)

Journal: BMC Immunology

Article Title: Prevention of M2 polarization and temporal limitation of differentiation in monocytes by extracellular ATP

doi: 10.1186/s12865-023-00546-3

Figure Lengend Snippet: The purinergic antagonists Suramin, PPADS, and KN62 did not have any significant effect on the production of CCL18 (A; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.) or Il-1ß (B; unstimulated vs. 10 µM Suramin n.s.; unstimulated vs. 10 µM PPADS n.s.; unstimulated vs. 250 nM KN62 n.s.). The pre-incubation of monocytes with inhibitors before ATP stimulation did not have any significant effect on the ATP-induced reduction in CCL18 levels (C; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, p = n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, p = n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, p = n.s.;) or on IL-1β levels (D; 100 µM ATP vs. 10 µM Suramin + 100 µM ATP, n.s.; 100 µM ATP vs. 10 µM PPADS + 100 µM ATP, n.s.; 100 µM ATP vs. 250 nM KN62 + 100 µM ATP, n.s)

Article Snippet: To block ATP-receptors, pyridoxalphosphate-6-azophenyl-2′,4′-disulphonic acid (PPADS, Tocris Bioscience), 1-(N,O-bis{5-isoquinolinesufonyll}-N-methyl-L-tyrosyl)-4-phenyl-piperazine (KN62, Tocris Bioscience) or Suramin (Tocris Bioscience) were added at indicated concentrations.

Techniques: Incubation